Research location
Thessaloniki
GR, Greece
Advertisement
Research activity in Thessaloniki
GR, GreeceCureCurrent currently publishes aggregate city-level research activity for this location: 23 trials and 32 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Thessaloniki
23 linked trials · page 1 of 1Dose-range Finding Efficacy and Safety Study for QBW251 in COPD PatientsNCT04072887 · 2019-09-12 · 1 site observation
COMPLETED
Systemic Corticosteroids Avoidance Study in Severe Asthma PatientsNCT03629249 · 2018-12-13 · 2 site observations
TERMINATED
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + TiotropiumNCT03158311 · 2018-02-05 · 3 site observations
COMPLETED
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma TreatmentNCT03052517 · 2017-03-21 · 1 site observation
TERMINATED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.NCT02555683 · 2015-12-11 · 1 site observation
COMPLETED
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaNCT02571777 · 2015-12-08 · 3 site observations
COMPLETED
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.NCT02563067 · 2015-12-03 · 1 site observation
COMPLETED
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPDNCT02603393 · 2015-11-20 · 1 site observation
COMPLETED
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.NCT02437318 · 2015-07-23 · 1 site observation
COMPLETED
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerNCT02278120 · 2014-11-20 · 1 site observation
COMPLETED
Global Non-interventional Heart Failure Disease RegistryNCT02595814 · 2014-07-23 · 1 site observation
TERMINATED
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD RegimenNCT01985334 · 2014-02-14 · 1 site observation
COMPLETED
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)NCT01782326 · 2013-07-01 · 1 site observation
COMPLETED
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase InhibitorNCT01610284 · 2012-08-07 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT01604278 · 2012-05-01 · 1 site observation
COMPLETED
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to FingolimodNCT01499667 · 2011-09-01 · 1 site observation
TERMINATED
Dose Finding Study for QAW039 in AsthmaNCT01437735 · 2011-08-01 · 1 site observation
COMPLETED
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisNCT01201356 · 2010-09-13 · 1 site observation
COMPLETED
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast CancerNCT01007942 · 2009-10-01 · 2 site observations
COMPLETED
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast CancerNCT00876395 · 2009-09-10 · 1 site observation
COMPLETED
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailureNCT00853658 · 2009-03-01 · 2 site observations
COMPLETED
Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)NCT02389933 · 3 site observations
NO_LONGER_AVAILABLE
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.